| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/18/2009 | EP1071955B2 Improved immunodiagnostic assays using reducing agents |
| 02/18/2009 | EP1027063B1 Mannose receptor bearing cell line and antigen composition |
| 02/18/2009 | EP0969866B2 Immunotherapy of b-cell malignancies using anti-cd22 antibodies |
| 02/18/2009 | EP0941337B1 Synthesis and purification of hepatitis c virus-like particles |
| 02/18/2009 | CN101370831A Methods and compositions for treating allergic diseases |
| 02/18/2009 | CN101370830A Human monoclonal antibodies to CD70 |
| 02/18/2009 | CN101370829A Chimeric and humanised anti-human IL-13 antibodies |
| 02/18/2009 | CN101370828A Anti-inflammatory dab |
| 02/18/2009 | CN101370827A Pharmaceutical compositions with resistance to soluble CEA |
| 02/18/2009 | CN101370826A Secreted frizzled related protein-4 (SFRP-4) protein binding agents |
| 02/18/2009 | CN101370521A Remedy for disease associated with choroidal angiogenesis |
| 02/18/2009 | CN101370519A Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer |
| 02/18/2009 | CN101370518A Immunologically active compositions |
| 02/18/2009 | CN101370517A Peptide derived from hepatitis C virus |
| 02/18/2009 | CN101370516A Soluble fragments of the SARS-CoV spike glycoprotein |
| 02/18/2009 | CN101370515A Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| 02/18/2009 | CN101370514A Neisseria meningitidis vaccines and their use |
| 02/18/2009 | CN101370513A Immunogenicity polypeptide composed of optimized concealed peptide derived from tumor antigen |
| 02/18/2009 | CN101368173A Antihuman CD44 monoclone antibody hybridoma cell line, monoclone antibody, engineering antibody, carrier, reagent kit and uses thereof |
| 02/18/2009 | CN101368167A Recombinant lactobacillus casei for co-expression of swine fever virus T cell epitope and pig parvoviral VP2 protein, and method of producing the same |
| 02/18/2009 | CN101367877A Monkey monoclonal antibodies specific to human B7.1 and/or B7.2 primatized forms, pharmaceutical compositions |
| 02/18/2009 | CN101367876A Monoclonal antiidiotypic antibody NP30 single-specificity double-chain antibody of Japanese blood fluke, preparation method and uses thereof |
| 02/18/2009 | CN101367874A Anti-amyloid antibodies, compositions, methods and uses |
| 02/18/2009 | CN101367869A Polypeptide for preventing, diagnosing and treating hepatitis E virus, and vaccine as diagnosis agent of the same |
| 02/18/2009 | CN101366945A Formulation method for adsorption diphtheria vaccine not containing methanal and thimerosal |
| 02/18/2009 | CN100462102C Mucosal meningococcal multivalence combined vaccines |
| 02/17/2009 | US7491801 Identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 02/17/2009 | US7491800 Cytokine zalpha11 ligand fusion proteins |
| 02/17/2009 | US7491798 Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins |
| 02/17/2009 | US7491707 Synthetic lipid-a-analogs and uses thereof |
| 02/17/2009 | US7491700 Contacting a cell with a peptide compound capable of inducing a conformational change in Bcl-2; converting the Bcl-2 into a pro-apoptotic form |
| 02/17/2009 | US7491554 Carrier of a diamond fine particle for immobilizing virus |
| 02/17/2009 | US7491550 Diagnostics and therapeutics for diseases associated with Neuromedin U2 receptor (NMU2) |
| 02/17/2009 | US7491537 Nucleic acid formulations for gene delivery and methods of use |
| 02/17/2009 | US7491525 Specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it |
| 02/17/2009 | US7491517 Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135 |
| 02/17/2009 | US7491516 Dual specificity antibodies and methods of making and using |
| 02/17/2009 | US7491515 Recombinant polypeptides for diagnosing infection with Trypanosoma cruzi |
| 02/17/2009 | US7491514 High specificity antibodies with reduce immunogenicity; evaluative and diagnostic tools; immunotherapy |
| 02/17/2009 | US7491511 isolated nucleic acid encoding a fungal antigen from Candida albicans; antiallergenic reaction to fungi in a vertebrate; and diagnosing a disease caused by fungi in a vertebrate; desensitization therapy for vaccines; insoluble cytoplasmic membrane proteins, free of cell wall |
| 02/17/2009 | US7491508 termini grow efficiently in desired cell line; left terminus spans the 5' inverted terminal repeat, left terminus spans the E4 region and the 3' inverted terminal repeat; internal regions does not grow efficiently in the desired cell; adenovirus vectors use for gene therapy; culturing; vaccines |
| 02/17/2009 | US7491500 Mammalian cytokine; related reagents |
| 02/17/2009 | US7491490 For inhibition of viral entry into cells |
| 02/17/2009 | US7491405 Antigenic protein originating in Malassezia |
| 02/17/2009 | US7491404 veterinary medicine; formaldehyde-inactivated and purified spores obtained from B. anthracis lacking pXO2 plasmids, having mutated pXO1 plasmids, said mutant strain of B. anthracis resulting in a gene incapable of producing EF and LF toxin or rendering said toxins inactive |
| 02/17/2009 | US7491403 containing a sequestration agent including proteins, lipids and carbohydrates, particularly albumin; treating neuromuscular diseases and pain |
| 02/17/2009 | US7491402 Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof |
| 02/17/2009 | US7491401 Lawsonia intracellularis vaccine |
| 02/17/2009 | US7491400 Pharmaceutical compositions comprising attenuated HIV-1 nef-deficient viral particles |
| 02/17/2009 | US7491399 introducing in ovo in poultry ovum a vaccine containing a recombinant virus comprising Segment A (SEQ ID NO: 5) modified to include nucleotide sequences from D78 and GLS strains and wherein the NS protein is not expressed, to protective against STC-IBDV |
| 02/17/2009 | US7491398 Proteins in enteroaggregative Escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections |
| 02/17/2009 | US7491397 Receptor binding polypeptides |
| 02/17/2009 | US7491396 peptides; reduced allergenic activity as compared to Phl p 2 wild type; vaccine; biodrug |
| 02/17/2009 | US7491395 Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination |
| 02/17/2009 | US7491394 Using copper binding protein as therapeutic tool in prevention of viral infection and treatment of cell proliferative disorders |
| 02/17/2009 | US7491393 Monoclonal antibody secific to lymphocyte peripheral membrane protein for treating and preventing transplant rejection, blood, skin, autoimmune, allergic and diabetic disorders |
| 02/17/2009 | US7491392 An isolated IL-1 beta binding molecule comprising a heavy chain variable domain; treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteroporosis and other inflammatory arthritis |
| 02/17/2009 | US7491391 Anti-IL-23 antibodies, compositions, methods and uses |
| 02/17/2009 | US7491390 Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| 02/17/2009 | US7491389 Bone marrow; controlling cell differentiation |
| 02/17/2009 | CA2346406C Detection of pleiotrophin |
| 02/17/2009 | CA2325983C Drug delivery of proteins from polymeric blends |
| 02/17/2009 | CA2316411C Humanized monoclonal antibodies that protect against shiga toxin induced disease |
| 02/17/2009 | CA2233166C Hormone immunomodulated induction of mucosal immune responses |
| 02/17/2009 | CA2164984C Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| 02/17/2009 | CA2138928C Immunoconjugates |
| 02/17/2009 | CA2121498C Recombitope peptides |
| 02/17/2009 | CA1341591C Detoxification of pertussis toxin |
| 02/15/2009 | CA2628900A1 Monoclonal antibodies against .beta.3 integrins |
| 02/12/2009 | WO2009021234A1 Methods of treatment and prevention of diet- induced obesity and sequelae thereof |
| 02/12/2009 | WO2009021230A1 Hiv-1 gp41 neutralization domain and use thereof |
| 02/12/2009 | WO2009021150A2 Platelet derived growth factor receptor supports cytomegalovirus infectivity |
| 02/12/2009 | WO2009021136A1 Chlorotoxins as drug carriers |
| 02/12/2009 | WO2009021022A2 Modulating the activity of nuclear receptors in order to treat hypoxia-related disorders |
| 02/12/2009 | WO2009020964A2 Anti-neublastin antibodies and uses thereof |
| 02/12/2009 | WO2009020748A2 Antibody therapy for modulating function of intestinal receptors |
| 02/12/2009 | WO2009020654A1 Compositions and methods for crystallizing antibodies |
| 02/12/2009 | WO2009020645A2 Matriptase protein and uses thereof |
| 02/12/2009 | WO2009020613A1 Modulation of cell junctions |
| 02/12/2009 | WO2009020455A1 Compositions and methods for microbe storage and delivery |
| 02/12/2009 | WO2009020391A1 Immunogenic streptococcus proteins |
| 02/12/2009 | WO2009020236A2 Baculoviral vectors with a dual vertebrate and baculovirus promoter controlling an immunogenic fusion gene |
| 02/12/2009 | WO2009020093A1 Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor |
| 02/12/2009 | WO2009020058A1 Drug delivery system toward demyelinating lesion and biochemical marker of demyelinating lesion |
| 02/12/2009 | WO2009019612A2 Lentiviral gene transfer vectors and their medicinal applications |
| 02/12/2009 | WO2009019317A1 Composition and therapeutic anti-tumour vaccine |
| 02/12/2009 | WO2009019312A2 Anti cd37 antibodies |
| 02/12/2009 | WO2009018625A1 Treatment of prion protein related diseases |
| 02/12/2009 | WO2009018623A1 Molecular markers and methods related thereto |
| 02/12/2009 | WO2009009739A3 Methods and compositions for facilitating cell death of cancer stem cells and for treating cancer |
| 02/12/2009 | WO2009002159A3 Intradermal hpv peptide vaccination |
| 02/12/2009 | WO2008156778A9 Influenza m2 protein mutant viruses as live influenza attenuated vaccines |
| 02/12/2009 | WO2008154638A3 Antagonists of the receptor for advanced glycation end-products (rage) |
| 02/12/2009 | WO2008145338A3 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 02/12/2009 | WO2008145137A3 Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering |
| 02/12/2009 | WO2008142162A3 Pharmaceutical agent for the treatment of fertility and gestation disorders, immunological diseases, and transplantation for use in veterinary medicine, particularly in horses, and methods for the production and treatment monitoring thereof |
| 02/12/2009 | WO2008134724A3 Methods for administering anti-il-5 antibodies |
| 02/12/2009 | WO2008134697A3 Prrsv vaccins based on gp5 proteins |
| 02/12/2009 | WO2008127450A3 Linear expression cassette vaccines |
| 02/12/2009 | WO2008115641A9 Modular nanoparticles for adaptable vaccines |